Cognito Therapeutics develops a non-invasive neuromodulation headset designed to influence brain activity associated with Alzheimer’s disease. The company’s approach uses synchronized light and sound stimulation to target neural circuits implicated in cognitive decline. Its platform is intended to be used repeatedly over time as a therapeutic intervention rather than as a diagnostic or wellness product. Cognito Therapeutics positions its technology within regulated clinical development pathways.

The technology delivers rhythmic audiovisual stimulation engineered to evoke gamma-band brain activity. By entraining neural oscillations through sensory pathways, the system aims to modulate network-level brain function linked to cognition and memory. This approach does not involve electrical stimulation or invasive interfaces, instead relying on patterned sensory input to influence neural dynamics. The headset is designed for consistent delivery of stimulation under controlled therapeutic protocols.

Cognito Therapeutics targets Alzheimer’s disease, with a focus on slowing cognitive decline, brain atrophy, and functional loss. The platform is intended for clinical use and evaluation rather than consumer wellness applications. Its positioning reflects growing interest in non-invasive neuromodulation strategies that seek to address neurodegenerative disease by restoring disrupted brain rhythms.